

Bart Clarke

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4216256/bart-clarke-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

5,879
citations

37
h-index

76
g-index

103
ext. papers

7,209
ext. citations

6.3
avg, IF

6.45
L-index

#	Paper	IF	Citations
90	The PARADIGM (physicians advancing disease knowledge in hypoparathyroidism) registry for patients with chronic hypoparathyroidism: study protocol and interim baseline patient characteristics. <i>BMC Endocrine Disorders</i> , 2021 , 21, 232	3.3	0
89	Research Involving Participants With Impaired Consent Capacity: An Examination of Methods to Determine Capacity to Consent. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2806-2822	6.4	1
88	Basal Ganglia Calcification Is Associated With Local and Systemic Metabolic Mechanisms in Adult Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 1900-1917	5.6	2
87	Hormonal regulation of biomineralization. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 261-275	15.2	14
86	The role of biomineralization in disorders of skeletal development and tooth formation. <i>Nature Reviews Endocrinology</i> , 2021 , 17, 336-349	15.2	8
85	Glucocorticoid- and Transplantation-Induced Osteoporosis. <i>Endocrinology and Metabolism Clinics of North America</i> , 2021 , 50, 251-273	5.5	0
84	Normocalcemic Primary Hyperparathyroidism: Need for a Standardized Clinical Approach. <i>Endocrinology and Metabolism</i> , 2021 , 36, 525-535	3.5	3
83	Ethical Challenges in COVID-19 Biospecimen Research: Perspectives From Institutional Review Board Members and Bioethicists. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 165-173	6.4	3
82	Basal ganglia calcification in hypoparathyroidism and pseudohypoparathyroidism: local and systemic metabolic mechanisms. <i>Journal of Endocrinological Investigation</i> , 2021 , 44, 245-253	5.2	4
81	Women With Chronic Hypoparathyroidism Have Low Risk of Adverse Pregnancy Outcomes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 3312-3319	5.6	2
80	PaTH Forward: A randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 ,	5.6	3
79	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Orthopaedic Trauma</i> , 2020 , 34, e125-e141	3.1	6
78	Bone metastases in thyroid cancer. <i>Journal of Bone Oncology</i> , 2020 , 21, 100282	4.5	26
77	Biomechanical Computed Tomography analysis (BCT) for clinical assessment of osteoporosis. <i>Osteoporosis International</i> , 2020 , 31, 1025-1048	5.3	20
76	Challenges in the management of chronic hypoparathyroidism. <i>Endocrine Connections</i> , 2020 ,	3.5	3
75	Stable interval bone density in patients with eosinophilic oesophagitis on topical steroids. <i>GastroHep</i> , 2020 , 2, 272-280	1	
74	Identification of osteoclast-osteoblast coupling factors in humans reveals links between bone and energy metabolism. <i>Nature Communications</i> , 2020 , 11, 87	17.4	53

73	Normocalcemic Hyperparathyroidism: A Heterogeneous Disorder Often Misdiagnosed?. <i>JBMR Plus</i> , 2020 , 4, e10391	3.9	8
72	Reply to Corticosteroid-Induced Osteonecrosis in COVID-19: A Call for Caution. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 2084-2085	6.3	
71	Strontium 2020 , 652-665		2
70	Secondary Fracture Prevention: Consensus Clinical Recommendations from a Multistakeholder Coalition. <i>Journal of Bone and Mineral Research</i> , 2020 , 35, 36-52	6.3	63
69	Safety and Efficacy of 5 Years of Treatment With Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019 , 104, 5136-5147	5.6	23
68	Transgender bone health. <i>Maturitas</i> , 2019 , 127, 35-42	5	6
67	A Lot of Progress, With More to Be Done: A Response to NIH Pathways to Prevention Report "Research Gaps for Long-Term Drug Therapies for Osteoporotic Fracture Prevention". <i>Journal of Bone and Mineral Research</i> , 2019 , 34, 1549-1551	6.3	4
66	Institutional Review Boards: What Clinician Researchers Need to Know. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 515-525	6.4	12
65	MANAGEMENT OF ENDOCRINE DISEASE: Hypoparathyroidism in pregnancy: review and evidence-based recommendations for management. <i>European Journal of Endocrinology</i> , 2019 , 180, R37-R44	6.5	22
64	Standards of care for hypoparathyroidism in adults: a Canadian and International Consensus. <i>European Journal of Endocrinology</i> , 2019 , 180, P1-P22	6.5	44
63	Asymptomatic Primary Hyperparathyroidism. <i>Frontiers of Hormone Research</i> , 2019 , 51, 13-22	3.5	11
62	Hypoparathyroidism and Other Causes of Hypocalcemia 2019 , 192-203		
61	Recombinant Human Parathyroid Hormone Effect on Health-Related Quality of Life in Adults With Chronic Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018 , 103, 722-731	5.6	39
60	Causes of low peak bone mass in women. <i>Maturitas</i> , 2018 , 111, 61-68	5	12
59	Epidemiology and Complications of Hypoparathyroidism. <i>Endocrinology and Metabolism Clinics of North America</i> , 2018 , 47, 771-782	5.5	18
58	Abaloparatide: Recombinant human PTHrP (1-34) anabolic therapy for osteoporosis. <i>Maturitas</i> , 2017 , 97, 53-60	5	13
57	Effects of parathyroid hormone rhPTH(1-84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. <i>Endocrine</i> , 2017 , 55, 273-282	4	32
56	Biochemical Testing Relevant to Bone. <i>Endocrinology and Metabolism Clinics of North America</i> , 2017 , 46, 649-667	5.5	4

55	Safety and Efficacy of Recombinant Human Parathyroid Hormone in Adults With Hypoparathyroidism Randomly Assigned to Receive Fixed 25- μ g or 50- μ g Daily Doses. <i>Clinical Therapeutics</i> , 2017 , 39, 2096-2102	3.5	12
54	Hypoparathyroidism. <i>Nature Reviews Disease Primers</i> , 2017 , 3, 17055	51.1	100
53	Melorheostosis: a Rare Sclerosing Bone Dysplasia. <i>Current Osteoporosis Reports</i> , 2017 , 15, 335-342	5.4	37
52	Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned. <i>Endocrine Reviews</i> , 2017 , 38, 325-350	27.2	114
51	Long-term outcomes in patients with multiple endocrine neoplasia type 1 and pancreaticoduodenal neuroendocrine tumours. <i>Clinical Endocrinology</i> , 2017 , 86, 199-206	3.4	17
50	Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. <i>Osteoporosis International</i> , 2017 , 28, 1-19	5.3	245
49	Bone Structural Characteristics and Response to Bisphosphonate Treatment in Children With Hajdu-Cheney Syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017 , 102, 4163-4172	5.6	18
48	Association of the serotonin transporter-linked polymorphic region genotype with lower bone mineral density. <i>Translational Psychiatry</i> , 2017 , 7, e1213	8.6	1
47	RIP140 in monocytes/macrophages regulates osteoclast differentiation and bone homeostasis. <i>JCI Insight</i> , 2017 , 2, e90517	9.9	11
46	Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 - case report and review of the literature. <i>Clinical Endocrinology</i> , 2016 , 84, 244-249	3.4	37
45	Management of Hypoparathyroidism: Summary Statement and Guidelines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2273-83	5.6	207
44	Epidemiology and Diagnosis of Hypoparathyroidism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016 , 101, 2284-99	5.6	148
43	Comprehensive Assessment of Osteoporosis and Bone Fragility with CT Colonography. <i>Radiology</i> , 2016 , 278, 172-80	20.5	42
42	Review of Hypoparathyroidism. <i>Frontiers in Endocrinology</i> , 2016 , 7, 172	5.7	62
41	AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS - 2016--EXECUTIVE SUMMARY. <i>Endocrine Practice</i> , 2016 , 22, 1111-8	3.2	115
40	Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 16-35	6.3	348
39	Bone biology, signaling pathways, and therapeutic targets for osteoporosis. <i>Maturitas</i> , 2015 , 82, 245-55	5	43
38	The Pathophysiology and Treatment of Osteoporosis. <i>Clinical Therapeutics</i> , 2015 , 37, 1837-50	3.5	149

37	Teriparatide Therapy and Reduced Postoperative Hospitalization for Postsurgical Hypoparathyroidism. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2015 , 141, 822-7	3.9	23
36	Epidemiology of Primary Hyperparathyroidism 2015 , 297-308		4
35	Serum 25-Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range. <i>Journal of Bone and Mineral Research</i> , 2015 , 30, 1119-33	6.3	111
34	Understanding the burden of illness associated with hypoparathyroidism reported among patients in the PARADOX study. <i>Endocrine Practice</i> , 2014 , 20, 671-9	3.2	76
33	Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3580-94	5.6	227
32	Pituitary Gland 2014 , 22-46		
31	Adrenal Gland 2014 , 47-75		
30	Bone and Mineral Metabolism 2014 , 100-154		
29	Gonads 2014 , 155-205		
28	Mucocutaneous Manifestations of Endocrine Disorders 2014 , 206-225		
27	Chronic Kidney Disease-Mineral and Bone Disorders (CKD-MBDs): What the Endocrinologist Needs to Know. <i>Endocrine Practice</i> , 2014 , 20, 500-16	3.2	9
26	Validation of a CT-derived method for osteoporosis screening in IBD patients undergoing contrast-enhanced CT enterography. <i>American Journal of Gastroenterology</i> , 2014 , 109, 401-8	0.7	42
25	Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1-84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study. <i>Clinical Therapeutics</i> , 2014 , 36, 722-36	3.5	39
24	25-Hydroxyvitamin D levels and acute cellular rejection in liver transplant patients. <i>Endocrine Practice</i> , 2014 , 20, 769-74	3.2	7
23	Bone disease in hypoparathyroidism. <i>Arquivos Brasileiros De Endocrinologia E Metabologia</i> , 2014 , 58, 545-52		14
22	Anti-sclerostin antibodies: utility in treatment of osteoporosis. <i>Maturitas</i> , 2014 , 78, 199-204	5	52
21	Epidemiology of primary hyperparathyroidism. <i>Journal of Clinical Densitometry</i> , 2013 , 16, 8-13	3.5	40
20	Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. <i>Lancet Diabetes and Endocrinology</i> , 2013 , 1, 275-83	18.1	181

19	Clinical utility of serum sclerostin measurements. <i>BoneKEy Reports</i> , 2013 , 2, 361		62
18	Corticosteroid-induced osteoporosis: an update for dermatologists. <i>American Journal of Clinical Dermatology</i> , 2012 , 13, 167-90	7.1	11
17	Trends in subtrochanteric, diaphyseal, and distal femur fractures, 1984-2007. <i>Osteoporosis International</i> , 2012 , 23, 1721-6	5.3	49
16	Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. <i>Journal of Bone and Mineral Research</i> , 2011 , 26, 2317-37	6.3	369
15	Vitamin D insufficiency. <i>Mayo Clinic Proceedings</i> , 2011 , 86, 50-60	6.4	486
14	FGF23 regulation of phosphorus homeostasis is dependent on PTH. <i>Endocrinology</i> , 2011 , 152, 4016-8	4.8	5
13	Physiology of bone loss. <i>Radiologic Clinics of North America</i> , 2010 , 48, 483-95	2.3	162
12	Female reproductive system and bone. <i>Archives of Biochemistry and Biophysics</i> , 2010 , 503, 118-28	4.1	110
11	New and emerging treatments for osteoporosis. <i>Clinical Endocrinology</i> , 2009 , 71, 309-21	3.4	5
10	Assessing the true impact of recurrent fractures on fracture risk. <i>Journal of Bone and Mineral Research</i> , 2009 , 24, 1512-4	6.3	1
9	Androgens and bone. <i>Steroids</i> , 2009 , 74, 296-305	2.8	161
8	Normal bone anatomy and physiology. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008 , 3 Suppl 3, S131-9	6.9	1082
7	Does the use of proton-pump inhibitors increase the risk of fracture?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2007 , 3, 564-5		
6	Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. <i>International Journal of Prosthodontics</i> , 2007 , 20, 115-22	1.9	12
5	Bone histomorphometric changes after liver transplantation for chronic cholestatic liver disease. <i>Journal of Bone and Mineral Research</i> , 2003 , 18, 2190-9	6.3	33
4	Predictors of bone mineral density in aging healthy men varies by skeletal site. <i>Calcified Tissue International</i> , 2002 , 70, 137-45	3.9	48
3	Thyroid Hormone Regulation of Islet Cell Hormone Metabolic Actions 2001 , 907-938		
2	Changes in quantitative bone histomorphometry in aging healthy men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1996 , 81, 2264-70	5.6	78

- 1 Distribution of noncollagenous proteins in the matrix of adult human bone: evidence of anatomic and functional heterogeneity. *Journal of Bone and Mineral Research*, **1993**, 8, 1019-29 6.3 131